samotolisib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug Namesamotolisib
Drug Alias NameLY-3023414
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsSerine/threonine-protein kinase mTOR inhibitors
TargetsPI3-kinase class ISerine/threonine-protein kinase mTOR
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursXanthogranuloma, Juvenile +[34] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteEli Lilly And CompanyNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursXanthogranuloma, Juvenile +[28] 
Inactive IndicationsProstatic NeoplasmsColonic NeoplasmsColorectal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A